Interferon β augments Tuberous Sclerosis Complex 2 (TSC2)-dependent inhibition of TSC2-null ELT3 and human lymphangioleiomyomatosis-derived cell proliferation

Molecular Pharmacology

Volumn 73, Issue 3, 2008, Pages 778-788

  Goncharova, Elena A ^a,b   Goncharov, Dmitry A ^a   Chisolm, Amelia ^a   Spaits, Matthew S ^a   Lim, Poay N ^a   Cesarone, Gregory ^a   Khavin, Irene ^a   Tliba, Omar ^a   Amrani, Yassine ^a   Panettieri Jr , Reynold A ^a   Krymskaya, Vera P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; INTERFERON BETA RECEPTOR ALPHA; INTERFERON BETA RECEPTOR BETA; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE P38; RAPAMYCIN; S6 KINASE; STAT1 PROTEIN; STAT3 PROTEIN; TUBERIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL CTRAIN ELT3; CELL CULTURE; CELL CYCLE; CELL LINE; CELL PROLIFERATION; CELL STRAIN LAM; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; LUNG FIBROBLAST; LYMPHANGIOLEIOMYOMATOSIS; MESENCHYME CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; RAT; SMOOTH MUSCLE FIBER;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITORY CONCENTRATION 50; INTERFERON-BETA; LEIOMYOMA; LYMPHANGIOLEIOMYOMATOSIS; MUSCLE, SMOOTH; MUTATION; PHOSPHORYLATION; PROTEIN KINASES; RATS; RECEPTORS, INTERFERON; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; SIROLIMUS; STATISTICS AS TOPIC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS; UTERINE NEOPLASMS;

EID: 40849097790     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.040824     Document Type: Article

References (40)

1. Amrani Y, Tliba O, Choubey D, Huang CD, Krymskaya VP, Eszterhas A, Lazaar AL and Panettieri RA Jr (2003) IFN-gamma inhibits human airway smooth muscle cell proliferation by modulating the E2F-1/Rb pathway. Am J Physiol Lung Cell Mol Physiol 284:L1063-L1071.
2. Dabora SL, Roberts P, Nieto A, Perez R, Jozwiak S, Franz D, Bissler J, Thiele EA, Sims K, and Kwiatkowski DJ (2002) Association between a high-expressing interferon-gamma allele and a lower frequency of kidney angiomyolipomas in TSC2 patients. Am J Hum Genet 71:750-758.
3. de Weerd NA, Samarajiwa SA, and Hertzog PJ (2007) Type I interferon receptors: biochemistry and biological functions. J Biol Chem 282:20053-20057.
4. Dunn GP, Bruce AT, Ikeda H, Old LJ, and Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991-998.
5. El-Hashemite N and Kwiatkowski DJ (2005) Interferon-{gamma}-Jak-Stat signaling in pulmonary lymphangioleiomyomatosis and renal angiomyolipoma: a potential therapeutic target. Am J Respir Cell Mol Biol 33:227-230.
6. El-Hashemite N, Zhang H, Walker V, Hoffmeister KM, and Kwiatkowski DJ (2004) Perturbed IFN-gamma-Jak-signal transducers and activators of transcription signaling in tuberous sclerosis mouse models: synergistic effects of rapamycin-IFN-gamma treatment. Cancer Res 64:3436-3443.
7. Goncharova EA, Ammit AJ, Irani C, Carroll RG, Eszterhas AJ, Panettieri RA, and Krymskaya VP (2002a) Phosphatidylinositol 3-kinase is required for proliferation and migration of human pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 283:L354-L363.
8. Goncharova EA, Goncharov DA, Eszterhas AJ, Hunter DS, Glassberg MK, Yeung RS, Walker CL, Noonan D, Kwiatkowski DJ, Chou MM, et al. (2002b) Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation: a role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J Biol Chem 277:30958-30967.
9. Goncharova EA, Goncharov DA, Noonan D, and Krymskaya VP (2004) TSC2 modulates actin cytoskeleton and focal adhesion through TSC1-binding domain and the Rac1 GTPase. J Cell Biol 167:1171-1182.
10. Goncharova EA, Goncharov DA, Spaits M, Noonan D, Talovskaya E, Eszterhas A, and Krymskaya VP (2006a) Abnormal smooth muscle cell growth in lymphangioleiomyomatosis (LAM): role for tumor suppressor TSC2. Am J Respir Cell Mol Biol 34:561-572.
11. Goncharova EA and Krymskaya VP (2008) Pulmonary lymphangioleiomyomatosis (LAM): progress and current challenges. J Cell Biochem, in press.
12. Goncharova EA, Lim P, Goncharov DA, Eszterhas A, Panettieri RA Jr, and Krymskaya VP (2006b) Assays for in vitro monitoring proliferation of human airway smooth muscle (ASM) and human pulmonary arterial vascular smooth muscle (VSM) cells. Nat Protoc 1:2905-2908.
13. Hartford CM and Ratain MJ (2007) Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther 82:381-388.
14. Hino O, Kobayashi T, Momose S, Kikuchi Y, Adachi H, and Okimoto K (2003) Renal carcinogenesis: genotype, phenotype and dramatype. Cancer Sci 94:142-147.
15. Inoki K, Corradetti MN, and Guan K-L (2005) Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 37:19-24.
16. Johnson SR (2006) Lymphangioleiomyomatosis. Eur Respir J 27:1056-1065.
17. Juvet SC, McCormack FX, Kwiatkowski DJ, and Downey GP (2007) Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans. Am J Respir Cell Mol Biol 36:398-408.
18. Karpusas M, Whitty A, Runkel L, and Hochman P (1998) The structure of human interferon-beta: implications for activity. Cell Mol Life Sci 54:1203-1216.
19. Kolb TM, Duan L, and Davis MA (2005) Tsc2 expression increases the susceptibility of renal tumor cells to apoptosis. Toxicol Sci 88:331-339.
20. Krymskaya VP (2003) Tumour suppressors hamartin and tuberin: intracellular signalling. Cell Signal 15:729-739.
21. Krymskaya VP (2008) Smooth muscle-like cells in lymphangioleiomyomatosis. Proc Am Thorac Soc 5:119-126.
22. Krymskaya VP, Ammit AJ, Hoffman RK, Eszterhas AJ, and Panettieri RA Jr (2001) Activation of class IA PI3K stimulates DNA synthesis in human airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 280:L1009-L1018.
23. Krymskaya VP and Shipley JM (2003) Lymphangioleiomyomatosis: a complex tale of serum response factor-mediated tissue inhibitor of metalloproteinase-3 regulation. Am J Respir Cell Mol Biol 28:546-550.
24. Kwiatkowski DJ, Zhang H, Bandura JL, Heiberger KM, Glogauer M, el-Hashemite N, and Onda H (2002) A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum Mol Genet 11:525-534.
25. Lee L, Sudentas P, and Dabora SL (2006) Combination of a rapamycin analog (CCI-779) and interferon-gamma is more effective than single agents in treating a mouse model of tuberous sclerosis complex. Genes Chromosomes Cancer 45:933-944.
26. Miloloza A, Rosner M, Nellist M, Halley D, Bernaschek G, and Hengstschlager M (2000) The TSC1 gene product, hamartin, negatively regulates cell proliferation. Human Molecular Genetics 9:1721-1727.
27. Platanias LC (2003) The p38 mitogen-activated protein kinase pathway and its role in interferon signaling. Pharmacol Ther 98:129-142.
28. Platanias LC (2005) Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 5:375-386.
29. Smyth MJ, Hayakawa Y, Takeda K, and Yagita H (2002) New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2:850-861.
30. Soucek T, Pusch O, Wienecke R, DeClue JE, and Hengstschlager M (1997) Role of the tuberous sclerosis gene-2 product in cell cycle control. J Biol Chem 272:29301-29308.
31. Stark GR, Kerr IM, Williams BRG, Silverman RH, and Schreiber RD (1998) How cells respond to interferons. Annu Rev Biochem 67:227-264.
32. Takaoka A and Taniguchi T (2003) New aspects of IFN-alpha/beta signalling in immunity, oncogenesis and bone metabolism. Cancer Sci 94:405-411.
33. Talon J, Horvath CM, Polley R, Basler CF, Muster T, Palese P, and Garcia-Sastre A (2000) Activation of interferon regulatory factor 3 is inhibited by the influenza A virus NS1 protein. J Virol 74:7989-7996.
34. Tapon N, Ito N, Dickson BJ, Treisman JE, and Hariharan IK (2001) The Drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation. Cell 105:345-355.
35. Taveira-DaSilva AM, Steagall WK, and Moss J (2006) Lymphangioleiomyomatosis. Cancer Control 13:276-285.
36. Thyrell L, Hjortsberg L, Arulampalam V, Panaretakis T, Uhles S, Dagnell M, Zhivotovsky B, Leibiger I, Grander D, and Pokrovskaja K (2004) Interferon α-induced apoptosis in tumor cells is mediated through the phosphoinositide 3-kinase/mammalian target of rapamycin signaling pathway. J Biol Chem 279:24152-24162.
37. Tliba O, Tliba S, Da Huang C, Hoffman RK, DeLong P, Panettieri RA Jr, and Amrani Y (2003) Tumor necrosis factor α modulates airway smooth muscle function via the autocrine action of interferon β. J Biol Chem 278:50615-50623.
38. Verma A, Kambhampati S, Parmar S, and Platanias LC (2003) Jak family of kinases in cancer. Cancer Metastasis Rev 22:423-434.
39. Wilderman MJ, Sun J, Jassar AS, Kapoor V, Khan M, Vachani A, Suzuki E, Kinniry PA, Sterman DH, Kaiser LR, et al. (2005) Intrapulmonary IFN-{beta} gene therapy using an adenoviral vector is highly effective in a murine orthotopic model of bronchogenic adenocarcinoma of the lung. Cancer Res 65:8379-8387.
40. Yan H, Frost P, Shi Y, Hoang B, Sharma S, Fisher M, Gera JF, and Lichtenstein AK (2006) Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis. Cancer Res 66:2305-2313.